

1 **Processing of the L1 52/55k protein by the adenovirus protease: a new**
2 **substrate and new insights into virion maturation**

3

4 **Running title:** Cleavage of L1 52/55k by the adenovirus protease

5

6 **Authors:**

7 Ana J. Pérez-Berná^a, Walter F. Mangel^b, William J. McGrath^b, Vito Graziano^b, Jane
8 Flint^c, Carmen San Martín^{a,#}

9

10 **Affiliations:**

11 ^aDepartment of Macromolecular Structure, Centro Nacional de Biotecnología (CNB-
12 CSIC), Darwin 3, 28049 Madrid (Spain)

13 ^bBiosciences Department, Brookhaven National Laboratory, Upton, New York 11973
14 (USA)

15 ^cDepartment of Molecular Biology, Princeton University, Princeton, New Jersey 08544
16 (USA)

17 [#]Corresponding author: Carmen San Martín, e-mail: carmen@cnb.csic.es

18

19 **Word count for abstract: 199**

20

21 **Word count for text (excluding references, table footnotes, and figure legends):**

22 **7141**

23

24

25

26 **Abstract**

27 Late in adenovirus assembly, the viral protease (AVP) becomes activated and cleaves
28 multiple copies of three capsid and three core proteins. Proteolytic maturation is an
29 absolute requirement to render the viral particle infectious. Here we show that the L1
30 52/55k protein, which is present in empty capsids but not in mature virions and is
31 required for genome packaging, is the seventh substrate for AVP. A new estimate on its
32 copy number indicates there are about 50 molecules of the L1 52/55k protein in the
33 immature virus particle. Using a quasi *in vivo* situation, *i.e.* the addition of recombinant
34 AVP to mildly disrupted immature virus particles, we show that cleavage of L1 52/55k
35 is DNA-dependent, as is the cleavage of the other viral precursor proteins, and occurs at
36 multiple sites, many not conforming to AVP consensus cleavage sites. Proteolytic
37 processing of L1 52/55k disrupts its interactions with other capsid and core proteins,
38 providing a mechanism for its removal during viral maturation. Our results support a
39 model in which the role of L1 52/55k protein during assembly consists in tethering the
40 viral core to the icosahedral shell, and in which maturation proceeds simultaneously
41 with packaging, before the viral particle is sealed.

42

43 Introduction

44 Adenovirus morphogenesis ends with a maturation step comprising proteolytic cleavage
45 of several capsid and core precursor proteins. Without these cleavages, the immature
46 particle lacks infectivity because of its inability to uncoat (1-3). Maturation primes the
47 viral particle for stepwise uncoating by facilitating penton release and by loosening the
48 condensed genome and its attachment to the icosahedral shell (4, 5). Proteolytic
49 processing is carried out by the adenovirus protease (AVP, or L3 23K protein) (6). In
50 human adenovirus type 2 (HAdV-2), AVP recognizes (M/I/L)XGX-G and
51 (M/I/L)XGG-X sequence motifs (7, 8). These sequences are present in the precursor
52 proteins pIIIa, pVI and pVIII in the icosahedral shell, as well as in the DNA binding
53 polypeptides pVII, pre- μ , and the terminal protein. These six precursor proteins have
54 been shown to be substrates for AVP. Another potential substrate, because it contains an
55 AVP consensus sequence motif, is polypeptide L1 52/55k.

56 The L1 52/55k protein in HAdV-2 is 415 residues in length, with an AVP consensus
57 cleavage site at the 351-352 position (LAGT-G). Although the molecular mass of L1
58 52/55k calculated from its sequence is 47 kDa, the protein was named by its
59 electrophoretic mobility; it moved as a doublet due to two different phosphorylation
60 states (9). L1 52/55k is part of the genome packaging machinery, together with
61 polypeptides IIIa, IVa2, L4 33k, and L4 22k (10-15). An L1 52/55k deleted construct
62 produces only empty capsids (10), and a thermosensitive mutation in the L1 52/55k C-
63 terminal region (*ts369*; 333-EL-336 to 333-GP-336) causes partial packaging (16). L1
64 52/55k binds to the viral packaging sequence *in vivo* and to the putative packaging
65 ATPase IVa2 *in vitro* (17-19). L1 52/55k contributes to the specificity of packaging,
66 possibly *via* an interaction with capsid protein IIIa (12, 20). Furthermore, L1 52/55k has
67 been reported to bind non-specifically to DNA, and to interact with pVII and its mature
68 form VII in infected cells (21). The interaction with DNA may not be direct, because L1
69 52/55k does not bind to the DNA packaging sequence *in vitro* (17-19).

70 L1 52/55k has been considered a putative scaffolding protein, because it is present in
71 empty particles in its full length form, but is absent from the mature virion (9). It is not a
72 *bona fide* scaffolding protein, however, since capsids of apparently the same size and
73 composition as empty wildtype particles assemble in its absence (10). Fully packaged,
74 immature particles produced by the HAdV-2 thermosensitive mutant *ts1* at non-

75 permissive conditions contain precursor versions of all AVP targets because the virus
76 particles do not contain AVP (3). They have been reported to also contain 2 copies of
77 full length L1 52/55k, compared to ~4 copies in partially packaged capsids and 50 in
78 empty capsids (9). Bands corresponding to molecular weights of 40 and 34 kDa are also
79 recognized by antibodies generated against L1 52/55k in empty or partially packaged
80 capsids (9, 10, 22)¹. The 34 kDa and some smaller protein species are also revealed in
81 overloaded Western blots of mature particles. The 40 kDa band would correspond to the
82 expected product of proteolysis by AVP at the consensus cleavage site. Both the full
83 length and 40 kDa bands disappear and are replaced by higher molecular weight species
84 in electrophoresis performed in the absence of β -mercaptoethanol, suggesting the
85 formation of disulfide-linked homodimers mediated by the only Cys residue (Cys24) in
86 L1 52/55k (9, 22). The 34 kDa band has been proposed to originate by an additional
87 cleavage at the N-terminus, because it does not react with antibodies against either
88 residues 9-22 or 402-415 in L1 52/55k, and its electrophoretic mobility is not sensitive
89 to non-reducing conditions, consistent with the absence of Cys24 (9, 22). However, the
90 actual processing of L1 52/55k by AVP has not been experimentally observed, nor is
91 the origin of the smaller bands recognized by anti L1 52/55k antibodies known.
92 Furthermore, it is not known what possible role the cleavage by AVP might have in the
93 ejection of the L1 52/55k protein and its fragments from the particle upon packaging of
94 the genome.

95 AVP has a unique mode of action. It is synthesized as an inactive enzyme (23). It uses
96 two cofactors for maximal enzyme activity: the 11-amino acid peptide pVIc, derived
97 from the C-terminus of the polypeptide VI precursor pVI, and the viral DNA. AVP is
98 activated when pVI slides on DNA into AVP bound to the same DNA (24). AVP,
99 partially activated by being bound to DNA, cleaves pVI at its N-terminus and then at its
100 C-terminus. Cleavage at the C-terminus releases pVIc, which then binds to the AVP that
101 cut it out. The AVP-pVIc complex then slides along DNA, processing the virus
102 precursor proteins also bound to the DNA (25). These experiments were done with fully
103 disrupted *tsI* particles after heating at 60°C (26). When immature *tsI* particles are
104 incubated at 47°C for 10 min, they release pentons and peripentonal hexons, but retain

¹ Notice that the bands described as 40 and 34 kDa in (Hasson *et al.*, 1992) are instead described as 47 and 40 kDa in (Sutjipto *et al.*, 2005). Here we use the nomenclature in (Hasson *et al.*, 1992) to avoid confusion with the calculated molecular mass of the full length L1 52/55k protein (47 kDa).

105 the spherical capsid arrangement (27). The viral genome remains inside the “whiffle
106 ball” particle in a highly condensed form attached to the shell (4). Since these mildly
107 disrupted particles have a structural organization close to that of the intact immature
108 capsid, while presenting openings that allow recombinant AVP access to its substrates
109 bound to the viral DNA, we now use them as an experimental system to follow the
110 action of AVP in detail in a more “quasi-*in vivo*” situation. These assays reveal that L1
111 52/55k is a previously unrecognized substrate for AVP, and provide new insights into
112 its role during viral maturation.

113

114

115 **Materials and Methods**

116

117 **Materials**

118 The gene for AVP was cloned and expressed in *Escherichia coli*, and the protein was
119 purified as described (26). Immature virus was obtained by propagating the HAdV-2 *tsI*
120 mutant in HeLa cells at 39.5° as described (27). Particles were purified by equilibrium
121 centrifugation in CsCl gradients, desalted on a 10DC column (Bio-Rad) and stored in 20
122 mM Hepes pH 7.8, 150 mM NaCl plus 10% glycerol at -70°C at a final concentration of
123 1×10^{13} viral particles per ml (vp/ml). An E1-deleted HAdV-5 vector (Ad5GL) was used
124 as a mature, structurally wild-type virus control (28). The following antibodies were
125 used for immunoassays: rat polyclonal anti-pVII (29); mouse anti-V serum (30); rabbit
126 anti-VIII N-terminal fragment (provided by U. F. Greber); rabbit anti-pVI (31); rabbit
127 anti-L1 55/52k (17); and rabbit anti-HAdV-5 fiber knob (32).

128

129 **Analysis of AVP function in disrupted *tsI* virus**

130 Immature *tsI* virus at a concentration of 1.6×10^{12} vp/ml were mildly disrupted by
131 heating at 47°C for 10 minutes, then incubated with 0.25 μ M AVP at 37°C for the
132 indicated times. Reactions were carried out in 10 mM Tris-HCl (pH 7.4), 20 mM NaCl,
133 10 mM EDTA and stopped by adding electrophoresis loading buffer. This is a
134 suboptimal condition for enzyme activity (better nearer pH 8) (26) and for one-
135 dimensional diffusion on DNA (better nearer pH 6) (25), but it allowed both sliding and
136 enzyme activity to occur at a rate that best revealed details of the maturation process.

137 To assess the role of DNA in L1 52/55k processing by AVP, viral DNA was removed
138 from the samples as follows. Viruses were either mildly or completely disrupted by
139 heating at 47°C or 60°C respectively for 10 min, and incubated overnight at 37°C with
140 50 μ g/ml DNase I (SIGMA D5025) in 10 mM Tris-HCl (pH 8.2), 5 mM MgCl₂. The
141 DNase was inactivated by adding 10 mM EDTA. After 30 min, 0.25 μ M AVP was
142 added, and the samples were incubated at 37°C for 24 hours. In the indicated cases,
143 purified *tsI* DNA was added after DNase inactivation at a final concentration of 50

144 ng/ml. For DNA isolation, 25×10^{10} *tsI* viral particles were treated with proteinase K at a
145 final concentration of 400 µg/ml, and the DNA was extracted by phenol/chloroform
146 precipitation.

147

148 **Protein electrophoresis and Western blot analysis**

149 To separate viral proteins, samples were boiled in Laemmli loading buffer and subjected
150 to electrophoresis under denaturing conditions (SDS-PAGE) in either 15% or 4–20%
151 (BioRad mini-Protean TGX) acrylamide gels. For Western blot analysis, proteins
152 resolved *via* SDS-PAGE were transferred to PVDF membranes and probed with the
153 required antibodies. Bound antibodies were detected with the corresponding secondary
154 antibody conjugated to alkaline phosphatase (Sigma), and the membranes were
155 developed using an alkaline phosphatase conjugate substrate kit (Bio-Rad Laboratories,
156 Hercules, CA) as recommended by the manufacturer.

157

158 **Protein identification by mass spectrometry**

159 Protein bands observed in SDS-PAGE were carefully excised from Coomassie-stained
160 4-20% acrylamide gradient gels and subjected to in-gel trypsin digestion according to
161 (33). The gel pieces were swollen in a digestion buffer containing 50 mM NH_4HCO_3
162 and 12.5 µg/ml of trypsin (modified porcine trypsin, sequencing grade, Promega,
163 Madison, WI) in an ice bath. After 30 min, the supernatant was removed, and 20 µl of
164 50 mM NH_4HCO_3 were added to the gel pieces. Digestion was allowed to proceed at 37
165 °C overnight. The reaction was stopped by adding a mixture of 50% ACN and 0.5%
166 TFA. The extracted peptides were dried by speed-vacuum centrifugation and
167 resuspended in 4 µl of MALDI solution (30% ACN + 15% isopropanol + 0.5 % TFA).
168 20% of each peptide mixture was deposited onto a 384-well OptiTOF™ Plate (Applied
169 Biosystems, Framingham, MA, USA) and allowed to dry at room temperature. A 0.8 µl
170 aliquot of matrix solution (3 mg/mL α -cyano-4-hydroxycinnamic acid in MALDI
171 solution) was then added and allowed to dry at room temperature.

172 Samples were automatically analyzed in an ABI 4800 MALDI TOF/TOF mass
173 spectrometer (ABSciex, Framingham, MA, USA) working in positive ion reflector

174 mode (ion acceleration voltage was 25 kV for MS acquisition and 2 kV for MS/MS).
175 Peptide mass fingerprinting and MSMS fragment ion spectra were smoothed and
176 corrected to zero baseline using routines embedded in the ABI 4000 Series Explorer
177 Software v3.6. Internal and external calibration allowed to reach a typical mass
178 measurement accuracy of <25 ppm. To submit the combined PMF and MS/MS data to
179 MASCOT software v.2.1 (Matrix Science, London, UK), GPS Explorer v4.9 was used.

180

181 **Negative staining electron microscopy**

182 Virus samples were heated at 47°C for 10 min, and incubated with either AVP 0.25 µM
183 in 10 mM Tris-HCl (pH 7.4), 20 mM NaCl, 10mM EDTA or only buffer for the
184 indicated times. Proteolysis was stopped by adding NaCl to a final concentration of 150
185 mM. Samples were adsorbed for 5 min onto glow-discharged collodion/carbon-coated
186 copper EM grids. The grids were transferred to a 2% uranyl acetate drop for negative
187 staining, dried and examined in a JEOL JEM 1011 transmission electron microscope.

188

189 **Quantification of L1 52/55k copy number in *tsI* particles**

190 For semi-quantitative determination of the amount of L1 52/55k protein in different
191 viral populations, identical quantities of purified wildtype or *tsI* capsids (estimated by
192 absorbance at 260 nm) were electrophoresed and silver stained, or probed with anti-V or
193 anti-L1 52/55k antibodies for Western blot as described above. Band intensities in the
194 silver stained gel images were measured with ImageJ (34). The area below each peak in
195 the intensity plot was measured and corrected for the background intensity measured in
196 a nearby area. Since in denaturing gel electrophoresis the full length L1 52/55k protein
197 runs at the same position as polypeptide V, to estimate the copy number of L1 52/55k in
198 full *tsI* viral capsids, we compared the intensity ratio between bands corresponding to
199 polypeptides pVII (VII in wildtype) and V, or IX and V in *tsI* and wildtype virions.
200 Given that Western blot assays indicated that L1 52/55k was not present in wt
201 (**Supplementary Fig. 1**), an estimation of the L1 52/55k content was derived from the
202 excess intensity in the *tsI* polypeptide V band.

203

204 **Southern blot**

205 Detection of viral DNA by Southern blotting was performed by standard methods (35).
206 Briefly, DNA was extracted from purified *tsI* virus by proteinase K-SDS digestion
207 followed by phenol-chloroform extraction. Purified DNA was electrophoresed on 1%
208 agarose gels, transferred to Hybond nylon filters, and probed with DraIII-digested *tsI*
209 DNA labeled with alkaline phosphatase in conjunction with chemiluminescent detection
210 with CDP-star (Amersham, RPN3680).

211

212 **Far Western blot**

213 Different fragments of L1 52/55k were obtained by AVP cleavage in disrupted *tsI*
214 capsids, followed by SDS-PAGE and extraction from gel as follows: immature *tsI* virus
215 particles at a concentration of 1.6×10^{12} vp/ml were mildly disrupted by heating at 47°C
216 for 10 minutes, then incubated with 0.25 μ M of AVP at 37°C in 10 mM Tris-HCl (pH
217 8.2), 1 mM EDTA for 24 hours. The sample was electrophoresed under denaturing
218 conditions (SDS-PAGE) in 4–20% acrylamide gradient gels. Unstained bands
219 corresponding to L1 52/55k proteolysis products were excised using as a reference the
220 stained first and last lanes of the gel. The gel pieces were washed 3 times and
221 maintained in elution buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1 mM EDTA; pH 7.5)
222 in a rotary shaker at 30°C overnight, then centrifuged at 10,000g for 10 minutes.

223 Proteins present in the supernatant were labeled using two methods. In the first method,
224 proteins were incubated overnight with rabbit anti-L1-52/55k in a rotary shaker at 4°C
225 and cross-linked by adding 0.5% formaldehyde. Protein-antibody complexes were
226 separated from free antibody by Sephacryl S-200HR gel filtration chromatography. In
227 the second method, proteins were incubated with sulfo-NHS-biotin overnight, and the
228 reaction was stopped by adding 10 mM Tris, pH 7.4. The excess biotin reagent was
229 removed using a desalting column.

230 Samples of mildly disrupted *tsI* virus, digested or not digested with AVP, were
231 electrophoresed and transferred to a nitrocellulose membrane as described for Western
232 blots. For renaturation, the membranes were washed and incubated overnight in
233 refolding buffer TBS-T (100 mM Tris HCl pH 7.6, 150 mM NaCl and 0.01% Tween-
234 20), with 10% glycerol and 5 mM 2-mercaptoethanol. Membranes were then blocked

235 with 0.05% Tween20 in PBS for 2 hours, BSA 1% (w/v) in PBS for another 2 hours,
236 and incubated with the labeled proteins overnight, at 4°C with agitation. Finally, the
237 membranes were incubated with either secondary antibody or streptavidin-HRP for 1
238 hour, and the bound probes were detected using an enhanced chemiluminiscence
239 method.

240

241 **L1 52/55k release assay**

242 Immature *tsI* particles at a concentration of 1.6×10^{12} vp/ml were mildly disrupted by
243 heating at 47°C for 10 minutes, then incubated overnight at 37°C with either 0.25 μ M
244 AVP in 10 mM Tris-HCl (pH 8.2), 10 mM NaCl, 10 mM EDTA or only buffer . The
245 samples were centrifuged at 20,200 g for 60 minutes at 4°C. The supernatant was
246 collected and concentrated using a speed-vacuum concentrator, and the sediment was
247 dissolved in 10 mM Tris-HCl (pH 8.2), 10 mM NaCl, 10 mM EDTA, before being
248 analyzed by SDS-PAGE, Western blot, or native electrophoresis in agarose gels.

249

250 **Results**

251 **Processing of proteins in mildly disrupted *tsI* particles by AVP**

252 Immature *tsI* particles (containing all protein precursors) were partially disrupted by
253 heating at 47°C for 10 minutes, and incubated with recombinant AVP as described in
254 Materials and Methods. In the reactions, there were approximately 94-100 AVP
255 molecules per viral particle, a ratio similar to that encountered *in vivo* (50 AVP/particle)
256 (36). Processing of the viral proteins was followed by denaturing electrophoresis and by
257 Western blot analysis to identify the precursors and their cleavage products.

258 Five minutes after addition of AVP, processing of the precursors pVI and pVII was
259 observed (**Fig. 1a** and **1b**). For pVI, processing started with the appearance of the
260 intermediate product corresponding to residues 33-250 (**Fig. 1b**), previously observed in
261 *in vitro* assays using purified recombinant AVP and pVI (24). The mature protein, VI,
262 appeared at $t = 30$ min, and became the dominant form after 1 hour of incubation,
263 although some precursor was still present in the sample until $t=5$ hours. For pVII,
264 precursor and mature forms coexisted for the first hour of AVP treatment, after which
265 only the mature form was observed. It was not possible to determine when cleavage of
266 pVIII started, because the available antibodies did not reveal its cleavage products. As
267 with pVII, pVIII was completely processed after 1 h of AVP incubation, judging by the
268 disappearance of the precursor band in western blots. For controls, treating intact *tsI*
269 virus with AVP produced no cleavages, even after 6 h of incubation (**Supplementary**
270 **Fig. 2**); neither did heat-disrupted *tsI* viruses incubated in the absence of AVP show
271 any proteolytic degradation (see **Fig. 3b**).

272 L1 52/55k is a potential substrate for AVP, as it contains an AVP consensus cleavage
273 sequence. Therefore, we probed disrupted *tsI* virus for this protein (**Fig. 1b**). Western
274 blot analysis using serum against L1 52/55k revealed the presence of a band
275 corresponding to the full length protein in *tsI* virus. After the addition of AVP, two
276 more bands appeared beginning 15-30 min later, consistent with a 40 kDa doublet
277 previously observed in (9) and (22). We named the bands in this doublet **F1a** and **F1b**
278 (Fragment 1 a and b). A 40 kDa species is expected if the protein is cleaved at the
279 consensus site. Consistent with this hypothesis, it has previously been shown that the 40
280 kDa doublet is not recognized by an antibody directed against the C-terminal region
281 (residues 402-405) of L1 52/55k (22). Here we show directly that indeed the expected

282 cleavage is produced by AVP. An additional band of 34 kDa apparent molecular mass
283 also appeared in the Western blots, that we call **F2**. This 34 kDa band recognized by
284 anti-L1 52/55k antibodies had also previously been observed (9, 22), but this is the first
285 direct proof that it originates from the proteolytic action of AVP. Furthermore, in
286 gradient SDS-PAGE (**Fig. 1c**), at least three other bands recognized by the anti-L1
287 52/55k serum were observed upon incubation with AVP (**Fig. 1d**): two with apparent
288 molecular masses larger than 30 kDa (**F3** and **F4**), and one of 18 kDa (**F5**). The
289 presence of these bands hints at cleavage at non consensus sites. Interestingly, even
290 after long incubations ($t \geq 5$ hours), a considerable amount of L1 52/55k in a variety of
291 forms, from full length to 18 kDa, was observed, although the dominant form seemed to
292 be the 40 kDa doublet bands. This is in contrast with the absence of L1 52/55k bands in
293 wildtype, mature particles, suggesting that during maturation *in vivo* the processed
294 forms of the L52/55k protein are somehow expelled, as opposed to them being
295 completely degraded inside the nascent virion.

296

297 **AVP cleaves L1 52/55k at non canonical sites**

298 To further investigate the nature of the detected L1 52/55k species, we scanned the
299 HAdV-2 L1 52/55k sequence (UniProt ID: P03262) for consensus AVP cleavage motifs
300 using the PATTINPROT server ([http://npsa-pbil.ibcp.fr/cgi-
301 bin/npsa_automat.pl?page=/NPSA/npsa_pattinprot.html](http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_pattinprot.html)). There are three important
302 positions in the AVP consensus cleavage sequences: P₄, P₂, and P₁-P₋₁ (**Table 1**). When
303 the search was restricted to 100% compliance to either of the two previously reported
304 AVP recognition patterns (7, 8), only the consensus cleavage at residues Thr351-
305 Gly352 was found, as expected. However, a search with relaxed pattern similarity
306 constraints yielded 13 more possible cleavage sites (**Table 1**). According to the
307 PATTINPROT similarity criteria, six sites at residues 36-37, 66-67, 353-354, 382-383,
308 384-385, and 398-399 had 75% similarity to the consensus patterns, with a wobble in
309 the P₄ position. The other seven predicted sites had a lower similarity level (62%). Six
310 of these (65-66, 71-72, 124-125, 275-276, 276-277, 300-301 and 380-381) had a wobble
311 in the P₂ position, while the remaining one (297-301) had a wobble in the P₁-P₋₁
312 position. Location of these sites in the protein sequence (**Fig. 2a**) revealed that the 14

313 possible cleavages were clustered in 2 regions at the N-terminus, 3 at the C-terminus,
314 and 3 more in the central part of the polypeptide chain.

315 The possible L1 52/55k proteolytic products according to the PATTINPROT prediction
316 of AVP consensus and non-consensus cleavage sites are shown in **Table 2**.
317 Interestingly, there is a substantial correspondence between the sizes of the predicted
318 fragments and the bands recognized by anti-L1 52/55k antibodies in Western blots. To
319 further assess this point, these bands were extracted from gels and analyzed by mass
320 spectrometry (MS). The MS analysis confirmed that the F1, F2, F3 and F4 bands were
321 derived from L1 52/55k. It was not possible to determine the identity of the F5 band.
322 The peptide fingerprint obtained for each of the identified bands (**Fig. 2a**) further
323 supported their identity as fragments derived from non-consensus cleavage sites.
324 Altogether, our analyses indicate the following cleavage scheme for L1 52/55k (**Fig.**
325 **2b**): first, and most frequently, the C-terminal region is cleaved. The consensus
326 cleavage would produce a 40.3 kDa fragment, corresponding to the lower band in the F1
327 doublet. Cleavage at either the 382 or 398 positions (**Table 2**) would explain the upper
328 band F1a in the doublet, although there is no MS confirmation for this hypothesis. Next,
329 the 36 N-terminal residues are removed to produce F2 (36.3 kDa), in agreement with
330 previous results showing that this band did not appear in Western blots using antibodies
331 against either the C-terminal or the N-terminal regions of L1 52/55k, and that its
332 electrophoretic mobility was not dependent on the presence of reducing agents,
333 indicating that the single Cys residue at position 24 (**Fig. 2**) was absent (9, 22).
334 Additional cleavages identified here, at the 66 and 124 positions, give rise to F3 (33.0
335 kDa) and F4 (26.1 kDa). Finally, removal of the C-terminal stretch 275-351 or 300-351
336 could produce the smallest fragment observed, F5. It is intriguing that F5, whose
337 identity could not be confirmed by MS, consistently appears at early times during AVP
338 incubation (**Fig. 1c, 1d**).

339 Our results are consistent with L1 52/55k being cleaved at eight positions, seven of
340 them not conforming to the previously determined consensus sequence pattern (7, 8).
341 Other authors have previously detected maturation cleavages in adenovirus where the P₄
342 residue in the pattern was Gln or Asn, instead of Met, Leu or Ile (37). Here we report
343 one cleavage site with Asn in the P₄ position, other sites with Ala, Gly, and possibly
344 even a charged residue, Glu (**Fig. 2a**). The successive cleavages of L1 52/55k by AVP
345 result in fragments with drastic differences in their isoelectric points (**Table 2**), as well

346 as in the removal of sequence motifs or regions relevant for protein function (**Fig. 2b**).
347 These include the only cysteine residue in the polypeptide chain; the two
348 phosphorylation sites (38); part of the IVa2 binding domain (12); part of the region
349 required for interaction with the viral packaging sequence (39); and the region
350 containing residues mutated in the thermosensitive mutant *ts369* (16).

351

352 **Cleavage of L1 52/55k by AVP requires the presence of dsDNA**

353 We have previously shown that the presence of dsDNA is required for both activation of
354 AVP and for cleavage of its substrates by AVP-pVIc complexes, when assayed in *tsI*
355 virus particles completely disrupted by heating at 60°C (24, 25). To see if this is also the
356 case for L1 52/55k, we analyzed by Western blot its processing by AVP in the presence
357 or absence of dsDNA (**Fig. 3**). As previously observed for other AVP substrates, when
358 *tsI* virus was completely disrupted and its dsDNA digested away by DNase treatment
359 (**Fig. 3a, lane 3**; and **Fig. 3b, lane 6**), no proteolytic products, including any processed
360 form of L52/55k, were observed after 24 hours of incubation with AVP. When, after
361 DNase treatment, the DNase was inactivated and purified *tsI* DNA was added back to
362 the reaction, full AVP activity was recovered, including processing of L52/55k (**Fig.**
363 **3b, lanes 4 and 5**). Therefore, cleavage of L1 52/55k by AVP is also dependent on
364 dsDNA.

365 An intriguing behavior was observed when instead of completely disrupting *tsI* by
366 heating at 60°C, we used milder disruption conditions, heating at 47°C. In this case,
367 treatment with DNase did not completely degrade the dsDNA, but instead fragments in
368 the 200-300 bp size range remained in the solution, presumably protected by
369 interactions with core proteins that are not disrupted in the whiffle ball particle (**Fig. 3a,**
370 **lane 2**) (40). In the presence of these small dsDNA fragments, partial cleavage of L1
371 52/55k was observed, with only fragments F1 and F2 revealed in the Western blot (**Fig.**
372 **3b, lane 3**). That is, cleaving at internal positions in the polypeptide (interior to the 36-
373 351 residue region) did not occur. In these conditions, digestion of the pVI, pVII and
374 pVIII precursors was also deficient or absent (**Fig. 3b, SDS-PAGE**). This result
375 indicates that AVP function is hindered by the lack of long stretches of dsDNA or by
376 less DNA being present. It has previously been shown that for AVP to perform its
377 function, both protease and substrate have to be bound to the same DNA molecule (24,

378 25). Therefore, a possible reason for this hindrance is the lack of physical space in the
379 short oligonucleotides to house both the activated AVP and its substrates, as well as
380 other DNA binding proteins. Another possible reason is that only those proteins with
381 the lowest equilibrium dissociation constants for binding to DNA will be bound to the
382 “small” amount of dsDNA left. In any case, the lack of minor, internal cleavages in L1
383 52/55k in a situation with limited access to dsDNA suggests that its interaction with the
384 genome changes as a consequence of the major cleavages induced by AVP.

385

386 **Cleavage of L1 52/55k impairs its interactions with other proteins in the viral** 387 **particle**

388 In the assays presented above, L1 52/55k protein was cleaved at multiple sites by the
389 viral protease, but extensive cleavage was not observed – rather, large L1 52/55k
390 fragments (over 17 kDa molecular weight) were present even after several hours of
391 incubation with AVP. However, no traces of L1 52/55k were found in the mature virion
392 in a variety of experiments (**Figs. 1b, 1d, 3b, 5**). Therefore, we sought to investigate
393 how the limited proteolysis of L1 52/55k can result in complete removal of all
394 fragments from the viral particle during *in vivo* assembly.

395 We have previously shown that *in vivo* maturation of adenovirus results in the removal
396 of protein interactions that stabilize both capsid and core structures (4, 27). Here, we
397 observe the same effect in our *in vitro* system. HAdV-2 *ts1* preparations were imaged
398 by negative staining EM after heating at 47°C during 10 minutes, and digestion with
399 AVP for different periods. As expected, in the absence of AVP, *ts1* capsids lost some
400 capsomers but largely retained their icosahedral organization. In contrast, after 45 min
401 incubation with AVP, the structural integrity of the capsids was lost, and fragmented,
402 flattened capsids were mainly observed, along with some unraveling cores (**Fig. 4a**).
403 From this experiment we conclude that *in vitro* processing by AVP in disrupted
404 immature virus particles weakens interactions stabilizing the viral particle, similar to the
405 effect of *in vivo* AVP processing during maturation. Additionally, we observe that the
406 multiple cleavages undergone by L1 52/55k result in fragments with different
407 electrostatic properties (**Table 2**) and in loss of relevant sequence domains (**Fig. 2b**).
408 These observations suggest that AVP-induced cleavages in L1 52/55k may diminish its

409 interactions with other viral proteins, or the viral DNA, facilitating its removal from
410 viral particles during maturation.

411 Further evidence supporting this hypothesis was obtained from experiments testing the
412 solubility of L1 52/55k before and after incubation with AVP (**Fig. 4b**). When heat
413 disrupted *tsI* was centrifuged, the supernatant contained vertex proteins (peripentonal
414 hexons, penton, IIIa, fiber, pVI), while cores (DNA, V, pVII) and presumably large
415 capsid fragments (hexons, pVI, pVIII, IX) appeared in the sedimented material. Western
416 blotting indicated that some L1 52/55k was released together with the vertices, but the
417 majority remained in the insoluble fraction. When the disrupted virus was treated with
418 AVP before centrifugation, the distribution of most viral components between
419 supernatant and pellet remained essentially unaltered. However, all L1 52/55k
420 fragments were solubilized, indicating that processing by AVP disrupts L1 52/55k
421 interactions with the other proteins, and also the viral genome.

422 Next, we addressed the interactions of the different L1 52/55K fragments with other
423 viral proteins using far Western blots (**Fig. 4c**). Disrupted *tsI* virus incubated with AVP
424 was subjected to SDS-PAGE, L1 52/55k fragments F1, F2 and F3 were extracted and
425 purified from gels, and labeled using either antibodies against L1 52/55k, or biotin. The
426 labeled L1 52/55k fragments were then used as probes against viral proteins from *tsI*,
427 processed or unprocessed by AVP. In all cases, the most intense signal was obtained
428 with bands corresponding to either full length or processed L1 52/55k, indicating a
429 strong tendency to form homooligomers. Additional, minor interactions were observed
430 with hexon, penton base, pVII and VII. Interestingly, bands for these minor interactions
431 became fainter as the L1 52/55k cleavages became more extensive. Interaction with
432 penton base was only observed with F1, the largest fragment analyzed, while for the
433 smallest (F3), virtually only self-interaction was observed. This result indicates that the
434 N-terminal region of L1 52/55k (residues 1-65) participates in interactions with hexon,
435 penton base and pVII/VII, but it is not required for self-interaction, in spite of
436 containing the single cysteine residue in the sequence. Binding of L1 52/55k to hexon
437 and penton base had not been previously described. The present analysis did not reveal
438 other known L1 52/55k binding partners, such as polypeptides IIIa and IVa2 (12, 19).
439 The signal for IVa2 may be obscured by the signal for L1 52/55k itself, since their
440 electrophoretic mobilities are similar. As for IIIa, it is possible that the far Western blot
441 refolding conditions did not produce the proper conformation to maintain the native

442 interactions. Nevertheless, the experiments presented here indicate that in the viral
443 particle, L1 52/55k maintains an extensive network of interactions, not only with itself,
444 but also with both shell (hexon, penton) and core proteins (pVII, VII), as well as with
445 the genome. This network is disrupted when L1 52/55k is processed by AVP, providing
446 a mechanism for scaffold ejection during maturation.

447

448 **Estimation of the L1 52/55k copy number in immature *tsI* particles**

449 In the course of both the present (**Fig. 1c**) and previous work (24), we noticed that bands
450 appearing upon incubation of *tsI* with AVP, consistent with L1 52-55k cleavage
451 products, were often visible by silver staining. This observation suggested the
452 possibility that *tsI* full particles might contain L1 52-55k in larger quantities than
453 expected from the copy number of 2 calculated in (9). Therefore, we decided to perform
454 a new analysis of the L1 52/55k copy number in *tsI* using gel band densitometry (**Fig.**
455 **5**). Taking into account that *tsI* contains only full length L1 52/55k protein; that wt
456 virions do not contain L1 52/55k; and that full length L1 52/55k and polypeptide V have
457 similar electrophoretic mobility (~50 kDa), we estimated the amount of L1 52/55k in *tsI*
458 by comparing the density ratio between the 50 kDa band and other bands corresponding
459 to proteins with known copy numbers and present in both viral species. The excess
460 protein content in the *tsI* 50 kDa band was attributed to L1 52/55k (**Table 3**). These
461 calculations indicated that immature particles contain more than 50 copies of L1 52/55k,
462 an order of magnitude more than previously reported (9).

463

464 **Discussion**

465 Adenovirus morphogenesis is a complex process involving a considerable number of
466 players. The final components of the HAdV-2 ~150 MDa mature particle include
467 multiple copies of seven different proteins in the icosahedral shell (hexon, penton base,
468 fiber, IIIa, VI, VIII, and IX), and three putative DNA condensing proteins bound to the
469 genome in the core (V, VII and μ) (41, 42). In addition, several other factors are
470 required to assemble the fully infectious particle. The concerted action of at least five
471 different proteins is required for successful genome packaging: IIIa (also a part of the
472 icosahedral shell), IVa2, L4 33k, L4 22k and L1 52/55k (10, 12-15, 20, 43). Finally,
473 proteolytic maturation carried out by AVP together with its cofactors (dsDNA and
474 pVI_C) is required to render the particle infectious, i.e. metastable and primed for
475 uncoating (2, 4, 23).

476 Here we have followed the processing of immature, fully packaged virus particles using
477 recombinant AVP. We have observed that in this *quasi-in vivo* system, processing of
478 polypeptide VI proceeds in two steps, from the precursor pVI to the intermediate iVI to
479 the mature form VI, as previously observed using purified, recombinant pVI (24).
480 However, the most novel information provided by this work links the genome
481 encapsidation and maturation processes, by showing that L1 52/55k is the seventh
482 substrate for AVP, and pointing to the effect of the AVP-induced cleavages on its
483 extrusion from the maturing particle.

484 Because L1 52/55k is easily detected in HAdV light density particles (considered
485 assembly intermediates) but is absent from the mature virion, it has been proposed to act
486 as a scaffolding protein (9). Scaffolding elements are crucial in the assembly of large,
487 complex capsids, and are best understood in the dsDNA bacteriophage and the
488 structurally related herpesvirus systems (44-46). Some of their functions include:
489 initiating assembly by nucleation of coat proteins; determining capsid size; and
490 stabilizing labile assembly intermediates. Although structural knowledge on scaffolding
491 proteins is scarce, studies on bacteriophage assembly indicate that they have a tendency
492 to form homo-oligomers; bind to major coat proteins and packaging machinery (47, 48);
493 and have non-specific dsDNA binding activity (49). Once their functions have been
494 fulfilled, scaffolding elements are released from the immature capsid, before or during
495 genome packaging. Release is often mediated by degradation by viral proteases and is

496 thought to occur by extrusion through channels in the immature shell. In some
497 bacteriophage, such as HK97, there are no separate scaffolding polypeptides. Instead,
498 specific domains in the coat protein aid in assembly initiation and elongation and are
499 proteolytically removed before packaging.

500 Adenovirus seems to use a dual scaffolding system, including both a detached
501 polypeptide (L1 52/55k) and flexible regions of minor coat proteins that are removed
502 during maturation (27, 41). We have previously shown that the immature *tsI* particle is
503 more stable than the mature one, largely due to a remarkable core compaction and the
504 presence of strong capsid-core interactions mediated by the pIIIa, pVI, pVII, pVIII and
505 pre- μ precursors (4, 5, 27). In these studies the presence of L1 52/55k was not
506 considered, as a very low copy number ($n=2$) had been reported in *tsI* full particles (9).
507 However, the results shown here indicate that there is a much larger quantity of L1
508 52/55k ($n=50$) in *tsI*, implying that L1 52/55k may also contribute to the higher stability
509 of the immature virus. Here we show for the first time that L1 52/55k is proteolytically
510 processed by AVP, and that this processing facilitates its removal from the assembled
511 particle by impairing interactions with other core and shell proteins and possibly with
512 the dsDNA genome itself. Thus, cleavage of L1 52/55k must be considered part of the
513 maturation process of adenovirus during which it is primed for uncoating.

514 Why our estimates for the copy number of the L1 52/55k protein in *tsI* virus differ from
515 previous reports is not clear. The highly dynamic and transitory nature of the L1 52/55k
516 protein in the virus makes its copy number difficult to measure. Several potential
517 problems could give rise to this disagreement. First, the amount of viral DNA per
518 virion, as maturation proceeds, is variable. Second, in the growth of *tsI* virus, slight,
519 local variations in temperature could allow some AVP to be packaged which would
520 decrease the amount of L1 52/55k protein. Finally, quantitating proteins by staining or
521 antibody reactivity can give variable results. In the future, other methods for
522 quantitating the copy number of L1 52/55k in *tsI* particles may help to settle this
523 discrepancy. For example, metabolic labeling by propagating the virus in the presence
524 of ^{35}S provided a very accurate stoichiometric analysis of the complete AdV mature
525 particle (50). However, the occurrence of polypeptides IVa2, V and L1 52/55k in a
526 narrow range of electrophoretic mobility may complicate the procedure. An alternative
527 method would be the use of quantitative mass spectrometry (51). For these studies,
528 representative tryptic peptides for the protein under study are synthesized, isotopically

529 labeled and mixed in known quantities with the viral sample. The mass spectrometry
530 signal intensities of the labeled peptides are compared with those of their unlabeled
531 partners, thus serving as internal controls for estimation of the abundance of the
532 corresponding unlabeled peptide in the virus. This methodology has also been used for
533 AdV, where it helped to determine the copy number of the low abundance polypeptide
534 IVa2 (52).

535 Incubation with recombinant AVP produced L1 52/55k fragments different from those
536 expected if the protein was cleaved at the single AVP consensus pattern in its sequence
537 (7). The observation of cleavages at sites not fully conforming to the consensus was not
538 that surprising, given that this phenomenon had already been observed (37, 53). The
539 four empirically identified fragments shown by MS to be derived from the L1 52/55k
540 protein were all derived by cleavage at the AVP consensus sequence near the C-
541 terminus, at position 351. Three of these fragments were also derived by a second
542 cleavage, near the N-terminus of L1 52/55k, at sites that resemble consensus cleavage
543 sites (**Fig. 2** and **Table 1**). In fact, all of the putative cleavage sites resemble AVP
544 consensus cleavage sites; they all contain 2 of the 3 determinants most preferred by the
545 proteinase. This observation argues that cleavage occurred by AVP and not by a
546 contaminating *E. coli* protease in the AVP preparation. Consistent with this conclusion
547 is that no cleavage by AVP occurred in disrupted virions treated with DNase (**Fig. 3**).
548 No *E. coli* protease is known to have a DNA-dependent activity, whereas DNA is a
549 cofactor for AVP activity (23-25). Since three of the four fragments were cleaved at the
550 AVP consensus sequence as well as a secondary site, it is possible that cleavage at the
551 consensus sequence resulted in a conformational change of the protein thereby exposing
552 several secondary cleavage sites. Indeed, one could hypothesize that this first
553 conformational change is the trigger for a cascade of cleavages required for release of
554 L1 52/55k fragments from the nascent virion.

555 The picture emerging from this and other work highlights the similarities and the
556 differences between adenovirus and bacteriophage/herpesvirus regarding assembly and
557 maturation. Adenovirus scaffolding elements, whether peptides attached to minor coat
558 proteins or polypeptide L1 52/55k, form part of an extensive network of interactions
559 between the icosahedral shell and the viral core. Like the phage P22, ϕ 29 or SPP1
560 scaffolding proteins (45), L1 52/55k has the ability to form homo-oligomers, either
561 mediated by sulfur bridges using its single cysteine (9) or not (**Fig. 4c**). Additionally, L1

562 52/55k interacts with coat and core proteins (**Fig. 4c**) (12, 21), as well as with other
563 elements of the packaging machinery (17), including the genome itself (21). The latter
564 property is a requisite for its functioning as an AVP substrate (**Fig. 3**) (25). L1 52/55k is
565 cleaved at multiple sites, including several non-consensus ones, by the viral protease
566 (**Fig. 2**), but the protein is not completely degraded (**Fig. 1**). Cleavages impair some of
567 its interactions, leading to release of L1 52/55k from the maturing particle, similar to the
568 release mechanism reported for herpesvirus (46). The exact nature of the altered
569 interactions is not known. However, it is noticeable that the different L1 52/55k
570 fragments have widely different charge values (**Table 1**), suggesting possible changes in
571 electrostatic interactions. Interestingly, in bacteriophage P22, electrostatic interactions
572 between scaffold and coat proteins have been directly observed in high resolution cryo-
573 EM studies (47).

574 In adenovirus, the existence of light density, empty or partially packaged capsids
575 containing immature protein precursors, together with the similarities between
576 polypeptide IVa2 and other packaging motors, point to a sequential packaging
577 mechanism similar to that of bacteriophage, with the dsDNA being pumped into a
578 preformed procapsid (13, 17, 43, 54-56). Unlike in bacteriophage, in adenovirus the
579 scaffolding protein L1 52/55k does not seem to be required for capsid assembly, nor for
580 incorporation of the packaging motor (10). Rather, L1 52/55k participates in bridging
581 the viral core to the shell (**Fig. 6**). A possible role for this protein during packaging
582 would then be to tether stably the partially packaged genome to the procapsid while
583 DNA pumping is taking place. Alternatively, in a concerted assembly and packaging
584 model, the role of L1 52/55k could be to recruit capsid proteins, or capsid fragments,
585 onto condensing core precursors. In any case, since binding to DNA of both AVP and
586 its substrates is required for proteolysis to occur (24, 25), scaffold maturation and
587 release must occur during or after genome encapsidation.

588 How are the large cleavage products from L1 52/55k ejected from the virus particle?
589 The final products of L1 52/55k proteolytic processing are rather large polypeptides,
590 ranging in size from 17 to 40 kDa. Cleavage and release of L1 52/55k is not a
591 requirement for successful packaging, since immature virus particles containing full
592 length L1 52/55k and genome are readily assembled in the *ts1* mutant. The immature
593 capsids of bacteriophage and herpesvirus have large openings (~4x2 nm), thought to be
594 used as extruding conduits for the scaffold proteins (45). These channels disappear due

595 to large conformational rearrangements occurring during maturation and packaging to
596 produce a tightly closed shell. Such a mechanism does not seem to exist in adenovirus.
597 Light density particles in CsCl gradients are thought to represent the adenovirus
598 procapsid, but their structure has not been solved. However, negative staining EM
599 images, for example those in (13), suggest that their gross organization is highly similar
600 to that of the mature virion. Empty and full capsids of the adenovirus-like bacteriophage
601 PRD1 have practically identical structures, as do the adenovirus mature and immature,
602 fully packaged viral particles (27, 57). Therefore, in adenovirus, building of the tightly
603 knit immature shell must proceed in such a way that a large opening is present until the
604 last stages of maturation, so that scaffold fragments can be released before building of
605 the icosahedral shell is completed. Once core and capsid precursors are brought
606 together, whether in a sequential or concerted manner, the DNA-bound AVP can be
607 activated by interaction with pVI_C; maturation and packaging would proceed in a
608 simultaneous fashion, and assembly would end by fitting a last capsid piece after
609 complete release of scaffold fragments. What this last capsid piece would be, and
610 whether the large opening matches the genome packaging channel, are questions that
611 remain to be answered.

612

613 **Acknowledgements**

614

615 This work was supported by grant BFU2010-16382 from the Ministerio de Economía y
616 Competitividad of Spain (to C. S. M.), and by National Institutes of Health Grants
617 R01AI41599 (to W. F. M.) and GM037705 (to S. J. F.). A. J. P.-B. was a recipient of a
618 Juan de la Cierva postdoctoral contract from the Ministerio de Ciencia e Innovación of
619 Spain.

620 We gratefully acknowledge U. F. Greber (University of Zurich, Switzerland), K. Nagata
621 (University of Tsukuba, Japan), R. Gerard (UT Southwestern Medical Center), P.
622 Ostapchuk and P. Hearing (Stony Brook University) for the gift of antibodies used in
623 this work. We are also thankful to Mario Ciordia, Ambra Lo Piano, Sylvia Ayora and
624 María López Sanz (CNB-CSIC) for help with mass spectrometry and Southern blot
625 analyses.

626

627 **References**

- 628 1. **Cotten M, Weber JM.** 1995. The adenovirus protease is required for virus entry
629 into host cells. *Virology* **213**:494-502.
- 630 2. **Greber UF, Webster P, Weber J, Helenius A.** 1996. The role of the
631 adenovirus protease on virus entry into cells. *EMBO J* **15**:1766-1777.
- 632 3. **Weber J.** 1976. Genetic analysis of adenovirus type 2 III. Temperature
633 sensitivity of processing viral proteins. *J Virol* **17**:462-471.
- 634 4. **Pérez-Berná AJ, Ortega-Esteban A, Menéndez-Conejero R, Winkler DC,
635 Menéndez M, Steven AC, Flint SJ, de Pablo PJ, San Martín C.** 2012. The
636 role of capsid maturation on adenovirus priming for sequential uncoating. *J Biol
637 Chem* **287**:31582-31595.
- 638 5. **Ortega-Esteban A, Perez-Berna AJ, Menendez-Conejero R, Flint SJ, San
639 Martín C, de Pablo PJ.** 2013. Monitoring dynamics of human adenovirus
640 disassembly induced by mechanical fatigue. *Sci Rep* **3**:1434.
- 641 6. **Webster A, Kemp G.** 1993. The active adenovirus protease is the intact L3 23K
642 protein. *J Gen Virol* **74 (Pt 7)**:1415-1420.
- 643 7. **Diouri M, Keyvani-Amineh H, Geoghegan KF, Weber JM.** 1996. Cleavage
644 efficiency by adenovirus protease is site-dependent. *J Biol Chem* **271**:32511-
645 32514.
- 646 8. **Webster A, Russell S, Talbot P, Russell WC, Kemp GD.** 1989.
647 Characterization of the adenovirus proteinase: substrate specificity. *J Gen Virol*
648 **70 (Pt 12)**:3225-3234.
- 649 9. **Hasson TB, Ornelles DA, Shenk T.** 1992. Adenovirus L1 52- and 55-
650 kilodalton proteins are present within assembling virions and colocalize with
651 nuclear structures distinct from replication centers. *J Virol* **66**:6133-6142.
- 652 10. **Gustin KE, Imperiale MJ.** 1998. Encapsidation of viral DNA requires the
653 adenovirus L1 52/55-kilodalton protein. *J Virol* **72**:7860-7870.
- 654 11. **Ostapchuk P, Anderson ME, Chandrasekhar S, Hearing P.** 2006. The L4
655 22-kilodalton protein plays a role in packaging of the adenovirus genome. *J
656 Virol* **80**:6973-6981.
- 657 12. **Ma HC, Hearing P.** 2011. Adenovirus structural protein IIIa is involved in the
658 serotype specificity of viral DNA packaging. *J Virol* **85**:7849-7855.
- 659 13. **Ostapchuk P, Almond M, Hearing P.** 2011. Characterization of Empty
660 adenovirus particles assembled in the absence of a functional adenovirus IVa2
661 protein. *J Virol* **85**:5524-5531.
- 662 14. **Wu K, Guimet D, Hearing P.** 2013. The Adenovirus L4-33K Protein Regulates
663 both Late Gene Expression Patterns and Viral DNA Packaging. *J Virol* **87**:6739-
664 6747.
- 665 15. **Guimet D, Hearing P.** 2013. The Adenovirus L4-22K Protein Has Distinct
666 Functions in the Posttranscriptional Regulation of Gene Expression and
667 Encapsidation of the Viral Genome. *J Virol* **87**:7688-7699.
- 668 16. **Hasson TB, Soloway PD, Ornelles DA, Doerfler W, Shenk T.** 1989.
669 Adenovirus L1 52- and 55-kilodalton proteins are required for assembly of
670 virions. *J Virol* **63**:3612-3621.
- 671 17. **Ostapchuk P, Yang J, Auffarth E, Hearing P.** 2005. Functional interaction of
672 the adenovirus IVa2 protein with adenovirus type 5 packaging sequences. *J
673 Virol* **79**:2831-2838.

- 674 18. **Perez-Romero P, Tyler RE, Abend JR, Dus M, Imperiale MJ.** 2005.
675 Analysis of the interaction of the adenovirus L1 52/55-kilodalton and IVa2
676 proteins with the packaging sequence in vivo and in vitro. *J Virol* **79**:2366-2374.
677 19. **Gustin KE, Lutz P, Imperiale MJ.** 1996. Interaction of the adenovirus L1
678 52/55-kilodalton protein with the IVa2 gene product during infection. *J Virol*
679 **70**:6463-6467.
680 20. **Wohl BP, Hearing P.** 2008. Role for the L1-52/55K protein in the serotype
681 specificity of adenovirus DNA packaging. *J Virol* **82**:5089-5092.
682 21. **Zhang W, Arcos R.** 2005. Interaction of the adenovirus major core protein
683 precursor, pVII, with the viral DNA packaging machinery. *Virology* **334**:194-
684 202.
685 22. **Sutjipto S, Ravindran S, Cornell D, Liu YH, Horn M, Schlupe T, Hutchins
686 B, Vellekamp G.** 2005. Characterization of empty capsids from a conditionally
687 replicating adenovirus for gene therapy. *Hum Gene Ther* **16**:109-125.
688 23. **Mangel WF, McGrath WJ, Toledo DL, Anderson CW.** 1993. Viral DNA and
689 a viral peptide can act as cofactors of adenovirus virion proteinase activity.
690 *Nature* **361**:274-275.
691 24. **Graziano V, Luo G, Blainey PC, Pérez-Berná AJ, McGrath WJ, Flint SJ,
692 San Martín C, Xie XS, Mangel WF.** 2013. Regulation of a Viral Proteinase by
693 a Peptide and DNA in One-dimensional Space: II. Adenovirus proteinase is
694 activated in an unusual one-dimensional biochemical reaction. *J Biol Chem*
695 **288**:2068-2080.
696 25. **Blainey PC, Graziano V, Pérez-Berná AJ, McGrath WJ, Flint SJ, San
697 Martín C, Xie XS, Mangel WF.** 2013. Regulation of a Viral Proteinase by a
698 Peptide and DNA in One-dimensional Space: IV. Viral proteinase slides along
699 DNA to locate and process its substrates. *J Biol Chem* **288**:2092-2102.
700 26. **Mangel WF, Toledo DL, Brown MT, Martin JH, McGrath WJ.** 1996.
701 Characterization of three components of human adenovirus proteinase activity *in*
702 *vitro*. *J Biol Chem* **271**:536-543.
703 27. **Pérez-Berná AJ, Marabini R, Scheres SHW, Menéndez-Conejero R,
704 Dmitriev IP, Curiel DT, Mangel WF, Flint SJ, San Martín C.** 2009.
705 Structure and uncoating of immature adenovirus. *J. Mol. Biol.* **392**:547-557.
706 28. **Seki T, Dmitriev I, Kashentseva E, Takayama K, Rots M, Suzuki K, Curiel
707 DT.** 2002. Artificial extension of the adenovirus fiber shaft inhibits infectivity in
708 coxsackievirus and adenovirus receptor-positive cell lines. *J Virol* **76**:1100-
709 1108.
710 29. **Haruki H, Gyurcsik B, Okuwaki M, Nagata K.** 2003. Ternary complex
711 formation between DNA-adenovirus core protein VII and TAF-Ibeta/SET, an
712 acidic molecular chaperone. *FEBS Lett* **555**:521-527.
713 30. **Lunt R, Vayda ME, Young M, Flint SJ.** 1988. Isolation and characterization
714 of monoclonal antibodies against the adenovirus core proteins. *Virology*
715 **164**:275-279.
716 31. **Burckhardt CJ, Suomalainen M, Schoenenberger P, Boucke K, Hemmi S,
717 Greber UF.** 2011. Drifting motions of the adenovirus receptor CAR and
718 immobile integrins initiate virus uncoating and membrane lytic protein exposure.
719 *Cell Host Microbe* **10**:105-117.
720 32. **Henry LJ, Xia D, Wilke ME, Deisenhofer J, Gerard RD.** 1994.
721 Characterization of the knob domain of the adenovirus type 5 fiber protein
722 expressed in *Escherichia coli*. *J Virol* **68**:5239-5246.

- 723 33. **Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M.** 2006. In-gel
 724 digestion for mass spectrometric characterization of proteins and proteomes. *Nat*
 725 *Protoc* **1**:2856-2860.
- 726 34. **Schneider CA, Rasband WS, Eliceiri KW.** 2012. NIH Image to ImageJ: 25
 727 years of image analysis. *Nat Methods* **9**:671-675.
- 728 35. **Lorincz AT, Lancaster WD, Temple GF.** 1986. Cloning and characterization
 729 of the DNA of a new human papillomavirus from a woman with dysplasia of the
 730 uterine cervix. *J Virol* **58**:225-229.
- 731 36. **Brown MT, McGrath WJ, Toledo DL, Mangel WF.** 1996. Different modes of
 732 inhibition of human adenovirus proteinase, probably a cysteine proteinase, by
 733 bovine pancreatic trypsin inhibitor. *FEBS Lett* **388**:233-237.
- 734 37. **Blanche F, Monegier B, Faucher D, Duchesne M, Audhuy F, Barbot A,**
 735 **Bouvier S, Daude G, Dubois H, Guillemin T, Maton L.** 2001. Polypeptide
 736 composition of an adenovirus type 5 used in cancer gene therapy. *J Chromatogr*
 737 *A* **921**:39-48.
- 738 38. **Bergstrom Lind S, Artemenko KA, Elfinch L, Zhao Y, Bergquist J,**
 739 **Pettersson U.** 2012. The phosphoproteome of the adenovirus type 2 virion.
 740 *Virology* **433**:253-261.
- 741 39. **Perez-Romero P, Gustin KE, Imperiale MJ.** 2006. Dependence of the
 742 encapsidation function of the adenovirus L1 52/55-kilodalton protein on its
 743 ability to bind the packaging sequence. *J Virol* **80**:1965-1971.
- 744 40. **Vayda ME, Flint SJ.** 1987. Isolation and characterization of adenovirus core
 745 nucleoprotein subunits. *J Virol* **61**:3335-3339.
- 746 41. **San Martín C.** 2012. Latest Insights on Adenovirus Structure and Assembly.
 747 *Viruses* **4**:847-877.
- 748 42. **Giberson AN, Davidson AR, Parks RJ.** 2012. Chromatin structure of
 749 adenovirus DNA throughout infection. *Nucleic Acids Res* **40**:2369-2376.
- 750 43. **Zhang W, Low JA, Christensen JB, Imperiale MJ.** 2001. Role for the
 751 adenovirus IVa2 protein in packaging of viral DNA. *J Virol* **75**:10446-10454.
- 752 44. **Johnson JE.** 2010. Virus particle maturation: insights into elegantly
 753 programmed nanomachines. *Curr Opin Struct Biol* **20**:210-216.
- 754 45. **Prevelige PE, Fane BA.** 2012. Building the machines: scaffolding protein
 755 functions during bacteriophage morphogenesis. *Advances in experimental*
 756 *medicine and biology* **726**:325-350.
- 757 46. **Brown JC, Newcomb WW.** 2011. Herpesvirus capsid assembly: insights from
 758 structural analysis. *Curr Opin Virol* **1**:142-149.
- 759 47. **Chen DH, Baker ML, Hryc CF, DiMaio F, Jakana J, Wu W, Dougherty M,**
 760 **Haase-Pettingell C, Schmid MF, Jiang W, Baker D, King JA, Chiu W.** 2011.
 761 Structural basis for scaffolding-mediated assembly and maturation of a dsDNA
 762 virus. *Proc Natl Acad Sci U S A* **108**:1355-1360.
- 763 48. **Sun Y, Parker MH, Weigele P, Casjens S, Prevelige PE, Jr., Krishna NR.**
 764 2000. Structure of the coat protein-binding domain of the scaffolding protein
 765 from a double-stranded DNA virus. *J. Mol. Biol.* **297**:1195-1202.
- 766 49. **Morais MC, Kanamaru S, Badasso MO, Koti JS, Owen BA, McMurray CT,**
 767 **Anderson DL, Rossmann MG.** 2003. Bacteriophage phi29 scaffolding protein
 768 gp7 before and after prohead assembly. *Nat Struct Biol* **10**:572-576.
- 769 50. **van Oostrum J, Burnett RM.** 1985. Molecular Composition of the Adenovirus
 770 Type-2 Virion. *J. Virol.* **56**:439-448.

- 771 51. **Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP.** 2003. Absolute
772 quantification of proteins and phosphoproteins from cell lysates by tandem MS.
773 *Proc Natl Acad Sci U S A* **100**:6940-6945.
- 774 52. **Christensen JB, Ewing SG, Imperiale MJ.** 2012. Identification and
775 characterization of a DNA binding domain on the adenovirus IVa2 protein.
776 *Virology* **433**:124-130.
- 777 53. **Ruzindana-Umunyana A, Imbeault L, Weber JM.** 2002. Substrate specificity
778 of adenovirus protease. *Virus research* **89**:41-52.
- 779 54. **Zhang W, Imperiale MJ.** 2000. Interaction of the adenovirus IVa2 protein with
780 viral packaging sequences. *J Virol* **74**:2687-2693.
- 781 55. **Christensen JB, Byrd SA, Walker AK, Strahler JR, Andrews PC, Imperiale**
782 **MJ.** 2008. Presence of the adenovirus IVa2 protein at a single vertex of the
783 mature virion. *J Virol* **82**:9086-9093.
- 784 56. **Ostapchuk P, Hearing P.** 2008. Adenovirus IVa2 protein binds ATP. *J Virol*
785 **82**:10290-10294.
- 786 57. **San Martín C, Huiskonen JT, Bamford JK, Butcher SJ, Fuller SD,**
787 **Bamford DH, Burnett RM.** 2002. Minor proteins, mobile arms and membrane-
788 capsid interactions in the bacteriophage PRD1 capsid. *Nat Struct Biol* **9**:756-
789 763.
- 790
- 791
- 792

793 **Figure legends**

794

795 **Figure 1. Time course of AVP activity on mildly disrupted *ts1* virus.** (a) A 15%
 796 acrylamide SDS-PAGE showing changes in the viral proteins upon incubation with
 797 AVP for the times indicated. (b) Western blot assays to follow proteolytic processing of
 798 pVI, pVII, pVIII and L1 52/55k, as indicated. (c) Time course analysis of AVP
 799 cleavages in a 4-20% gradient gel. Double stars indicate bands generated upon
 800 incubation with AVP that could correspond to L1 52/55k cleavage products. (d)
 801 Western blot for L1 52/55k protein on a 4-20% gradient gel reveals more AVP
 802 generated proteolysis products. L1 52/55k full length precursor (FL) and fragment
 803 products (F1 to F5) are indicated in (b) and (d). (e) Control experiment. No proteolytic
 804 processing is observed in intact *ts1* virions in the presence of AVP, even after 6 hours of
 805 incubation. This observation also indicates that the virus particle is sealed, at least to a
 806 protein the size of AVP.

807

808 **Figure 2. Cleavage pattern of L1 52/55k by AVP.** (a) Location in the L1 52/55k
 809 sequence of the predicted AVP cleavage motifs and of the actual peptides identified by
 810 MS/MS in the different fragments generated by AVP cleavage. The possible cleavage
 811 sites predicted by PATTINPROT are indicated by vertical red lines. A thick, continuous
 812 line indicates the consensus site. Thick dashed lines indicate sites with 75% similarity to
 813 the consensus pattern. Thin dashed lines indicate sites with 62% similarity to the
 814 consensus pattern. The peptides identified for each fragment are indicated by horizontal
 815 lines below the sequence in different colors: blue for F1, orange for F2, green for F3 and
 816 magenta for F4. The single Cys residue is highlighted in green and the two
 817 phosphorylated Ser residues in light blue. (b) Schematics picturing the L1 52/55k
 818 sequence and cleavage products observed in this work. The box at the top represents the
 819 full length sequence with some relevant motifs or regions indicated as follows: pink,
 820 domain required for genome packaging (39); orange, IVa2 interacting domain (12);
 821 green, Cys residue involved in homodimer formation; blue, phosphorylated Ser
 822 residues; and dark red, residues involved in the *ts369* mutation (16). The fragment
 823 assignment and molecular weight are indicated in the center of each box. Initial and

824 final positions in the L1 52/55k sequence are indicated at left and right of each box.
 825 Stars indicate fragments identified by MS/MS.

826 **Figure 3. DNA requirement for L1 52/55k cleavage by AVP.** (a) DNA present in the
 827 preparations. DNA was extracted from either intact or heat disrupted *tsI* virus particles
 828 after DNase treatment, and revealed by Southern blot with a viral genome probe. Lane
 829 1: intact virus. Lane 2: virus disrupted at 47°C. Lane 3: virus disrupted at 60°C. (b)
 830 SDS-PAGE (top) and Western blot for L1 52/55k (bottom) showing dependence on
 831 DNA of AVP activity. Lane 1: control wildtype virus. Lane 2: control, intact untreated
 832 *tsI* virus. Lane 3: *tsI* virus disrupted at 47°C, DNase treated and then incubated with
 833 AVP. Lane 4: *tsI* virus disrupted at 60°C, treated with DNase, DNase inactivated, and
 834 purified DNA added back before incubation with AVP. Lane 5: *tsI* virus disrupted at
 835 60°C and incubated with AVP. Lane 6: *tsI* virus disrupted at 60°C, treated with DNase
 836 and incubated with AVP. Lane 7: *tsI* virus disrupted at 60°C, incubated with buffer in
 837 the absence of AVP.

838

839 **Figure 4. Effect of L1 52/55k cleavage in L1 52/55k associations with other**
 840 **components of the viral particle.** (a) EM images showing additional disruption of *tsI*
 841 particles heated at 47°C upon incubation with AVP for 45 min. The inset shows an
 842 unraveling core. The bar represents 200 nm. (b) Solubility of L1 52/55k and its cleavage
 843 products. Mildly disrupted *tsI* virus, control or treated with AVP, was centrifuged. The
 844 input (I), supernatant (S) and pellet (P) were analyzed by native DNA electrophoresis,
 845 SDS-PAGE, and Western blot with antibodies against fiber, L1 52/55k, or polypeptide
 846 V, as indicated. (c) Far Western blot assays to analyze interactions between L1 52/55k
 847 cleavage products and other proteins in the viral particle. The proteins in control or
 848 AVP treated *tsI* virus samples were separated by SDS-PAGE, and probed with gel-
 849 purified L1 52/55k F1, F2 and F3 fragments, previously labeled with either antibodies
 850 against L1 52/55k or biotin, as indicated.

851

852 **Figure 5. Estimation of L1 52/55k copy number.** Serial dilutions of wildtype (wt) or
 853 *tsI* virus samples were analyzed by SDS-PAGE and band densitometry, as well as by
 854 Western blot for L1 52/55k or polypeptide V, as indicated. The intensity ratio between

855 the bands labeled in the SDS_PAGE panel was used for the estimation, as explained in
856 the text.

857 **Figure 6. Cartoon summarizing the multiple interactions established by L1 52/55k**
858 **in the viral particle.** The figure is based both in results presented here and in
859 previously published studies (see text for details).

860

861

862 **Tables**

863

864 **Table 1:** Potential AVP cleavage sites in L52/55k predicted by PATTINPROT.
 865 Discrepancies from the consensus patterns are in **bold**.

866

Position relative to cleavage site (--)	$P_4P_3P_2P_1--P_{-1}$
AVP consensus cleavage sequences	(M/I/L)XGX--G (M/I/L)XGG--X
Major cleavage sequence in the L1 52/55k protein	LAGT--G
Wobble in the P_4 position	ASGG--A
	EEGE--G
	GTGS--G
	AAGA--G
	GAGP--G
Wobble in the P_2 position	NVGG--V
	LEEG--E
	LARL--G
	LRHG--L
	MLSL--G
Wobble in the P_1 - P_{-1} position	LSLG--K
	LEAA--G
Wobble in the P_1 - P_{-1} position	IEGF--Y

867

868

869 **Table 2:** Possible L1 52/55k fragments derived from AVP cleavage at the
 870 PATTINPROT predicted sites, and their correspondence to bands observed in Western
 871 blots after *in vitro* processing of mildly disrupted *tsI* virus by AVP. The isoelectric
 872 point value for each fragment is indicated. A star (*) indicates identification by mass
 873 spectrometry.

Fragment	Calculated molecular weight (kDa)	pI	Possible correspondence to Western blot band
1-415 (full length)	46.9	5.67	Full length
1-398	44.9	7.24	F1a
1-382	43.5	6.89	F1a
1-351 (consensus)	40.3	7.92	F1b*
36-351	36.3	6.66	F2*
66-351	33.0	8.77	F3*
124-351	26.1	6.74	F4*
124-300	20.2	5.55	F5
124-275	17.2	5.04	F5
275-351	8.9	9.91	Not observed

874

875

876 **Table 3:** Estimation of L1 52/55k copy number in *tsI*/virus

877

	wt virus		<i>tsI</i> /virus		Deduced L1 52/55k copy number in <i>tsI</i> virus (3)
	Theoretical mass ratio (1)	Calculated mass ratio (2)	Theoretical mass ratio (1)	Calculated mass ratio (2)	
VII/V	2.84	2.64 ± 0.20	2.50	2.12 ± 0.09	53 ± 5
IX/V	0.53	0.51 ± 0.04	0.53	0.34 ± 0.03	55 ± 3

878

- 879 (1) Calculated from the corresponding protein molecular mass (M) and copy numbers
 880 (N) as follows: in wt, $ratio_{VII/V} \approx (M_{VII} * N_{VII}) / (M_V * N_V)$; in *tsI*,
 881 $ratio_{pVII/V} \approx (M_{pVII} * N_{pVII}) / (M_V * N_V)$; in both, $ratio_{IX/V} \approx (M_{IX} * N_{IX}) / (M_V * N_V)$. The
 882 following values were used: $M_V = 41.0$ kDa; $M_{pVII} = 22.0$ kDa; $M_{VII} = 19.4$ kDa;
 883 $M_{IX} = 14.3$ kDa; $N_V = 157$; $N_{pVII} = N_{VII} = 833$; $N_{IX} = 240$.
- 884 (2) Calculated from the optical density values (D) of gel bands as measured with
 885 ImageJ, for example: $ratio_{VII/V} \approx D_{VII} / D_V$. The results report the average and
 886 standard deviation values from three independent electrophoresis assays.
- 887 (3) Calculated by solving the following equations for N_{L1} :
 888 $ratio_{pVII/(V+L1)} \approx D_{pVII} / D_{(V+L1)} \approx (M_{pVII} * N_{pVII}) / (M_V * N_V + M_{L1} * N_{L1})$; and $ratio_{IX/(V+L1)} \approx$
 889 $D_{IX} / D_{(V+L1)} \approx (M_{IX} * N_{IX}) / (M_V * N_V + M_{L1} * N_{L1})$, with $M_{L1} = 47.0$ kDa.

890











